Related by context. All words. (Click for frequent words.) 63 angiotensin converting enzyme inhibitors 62 ATACAND 62 mycophenolate mofetil MMF 61 β blockers 61 antihypertensive therapy 61 erythropoietic 61 mycophenolate mofetil 60 Ranolazine 60 cranial irradiation 60 COPD exacerbations 60 paricalcitol 60 ACE Inhibitor 60 T1DM 60 biologic DMARD 60 CsA 60 ULORIC 60 DOXIL 60 BENICAR 60 angiotensin II receptor blockers 60 cinacalcet 59 acromegalic patients 59 Telmisartan 59 adalimumab 59 olmesartan 59 fludarabine cyclophosphamide 59 renoprotective 59 vasopressor 59 pentoxifylline 59 oral prednisolone 59 HMG CoA reductase inhibitors 59 plus medroxyprogesterone acetate 59 UDCA 59 Teriflunomide 59 fluvastatin 59 HSCT 59 aldosterone antagonists 59 metastatic malignant 59 APTIVUS ritonavir 59 primary aldosteronism 59 angiotensin receptor blocker ARB 59 abacavir Ziagen 59 azacitidine 59 Elitek 59 irbesartan 59 Doxil ® 59 glucocorticoid therapy 59 beta blocker therapy 59 systemic corticosteroids 58 ß blockers 58 corticosteroid dose 58 somatostatin analog 58 polyarticular 58 antihypertensive medications 58 colorectal adenoma 58 Aggrenox ® 58 antiarrhythmic drug 58 intratympanic 58 xanthine oxidase inhibitor 58 antiandrogens 58 CIMZIA ™ 58 QVAR ® 58 ARIXTRA 58 AVONEX ® 58 tiotropium bromide 58 BPS IC 58 antioxidant supplementation 58 thyrotropin 58 transaminase elevations 58 tocilizumab 58 SGPT 58 bile acid sequestrant 58 cholinesterase inhibitor 58 inhaled budesonide 58 relapsing multiple sclerosis 58 antithrombotic therapy 58 topical calcineurin inhibitors 58 BENICAR HCT 58 beclomethasone dipropionate 58 ulcerative colitis UC 57 GH deficiency 57 Adalimumab 57 titrated glipizide 57 plasma renin activity 57 APTIVUS 57 ipratropium bromide 57 salmeterol fluticasone propionate 57 AST ALT 57 cisplatin gemcitabine 57 Cloretazine 57 intravenous bisphosphonates 57 IMiDs ® compound 57 serum creatinine levels 57 unstable angina UA 57 bronchial hyperresponsiveness 57 CIMZIA TM 57 Community Acquired Pneumonia 57 angiotensin receptor blockers 57 ara C 57 KAPIDEX 57 methotrexate therapy 57 ALRI 57 acute myocardial infarction MI 57 androgen suppression 57 ACEIs 57 Severe Primary IGFD 57 cardiovascular calcification 57 DMARD 57 TNF antagonist 57 dalteparin 57 eplerenone 57 Nilotinib 57 canakinumab 57 ADHF 57 T2DM 57 Severe Asthma 57 riociguat 57 sUA 57 left ventricular dysfunction 57 COPAXONE R 57 Salmeterol 57 euthyroid 57 CTEPH 57 epoetin alpha 57 macrolide antibiotic 57 thiazide 57 clomipramine 57 somatostatin analogs 57 Lenalidomide 57 glatiramer acetate GA 57 serum IGF 57 thromboembolic events 57 angiotensin converting enzyme ACE 57 macroalbuminuria 57 dimeglumine 57 severe exacerbations 57 lanthanum carbonate 56 nicardipine 56 decitabine 56 methimazole 56 severe oral mucositis 56 6R BH4 56 rilonacept 56 pyrazinamide 56 Primary endpoints 56 HMG CoA reductase inhibitor 56 thalidomide Thalomid 56 CDAI 56 Chronic Heart Failure 56 hyperphenylalaninemia HPA due 56 CALGB # [002] 56 Natalizumab 56 albumin excretion rate 56 antithyroid 56 dual endothelin receptor antagonist 56 glatiramer acetate 56 beta2 agonist 56 ARESTIN ® 56 inotropic 56 sorafenib Nexavar 56 inhaled corticosteroid therapy 56 NATRECOR R 56 Pemetrexed 56 Index CDAI 56 adalimumab Humira 56 Hydroxyurea 56 NSTEMI 56 candesartan cilexetil 56 progressive PsA 56 bioavailable testosterone 56 Cyclosporine 56 beta 1a 56 CREON R 56 FAMPYRA 56 methotrexate monotherapy 56 hereditary deficiency 56 EFFEXOR XR 56 loop diuretics 56 albumin excretion 56 Certolizumab pegol 56 ibandronate 56 loop diuretic 56 carotid IMT 56 selenium supplementation 56 nondiabetic patients 56 VAPRISOL 56 renal dysfunction 56 atherothrombotic disease 56 IFN beta 56 thromboprophylaxis 56 Bronchiectasis 56 relapsed MM 56 Patient Registry 56 tiotropium 56 Geodon ziprasidone 56 microalbuminuria 56 bendamustine 56 hypertonic saline 56 daunorubicin 56 cardiac toxicity 56 oral anticoagulation 56 bronchodilation 56 angiotensin II receptor antagonist 56 cis retinoic acid 56 Hepatotoxicity 56 glucocorticoid 56 Exacerbations 56 conjugated equine estrogen 56 darunavir r 56 medroxyprogesterone acetate 56 dyslipidaemia 56 QVAR R 56 BCR ABL inhibitor 56 surrogate endpoint 56 recurrent glioblastoma multiforme 56 Tracleer R 56 Noxafil 56 cisplatin chemotherapy 56 thromboembolic complications 56 vulvovaginal atrophy 56 Candesartan 55 pCR 55 IPAH 55 AECB 55 candesartan 55 Myelodysplastic Syndrome MDS 55 psoriatic arthritis PsA 55 thromboembolism 55 efalizumab 55 phenelzine 55 achieved ACR# 55 RoACTEMRA 55 Thiazolidinediones 55 acadesine 55 postoperative AF 55 QTc interval 55 neoadjuvant treatment 55 thrombus aspiration 55 adrenal insufficiency 55 tacrolimus ointment 55 See CLINICAL PHARMACOLOGY 55 tolvaptan 55 nephrotoxicity 55 leukocyte count 55 antiepileptics 55 insulin detemir 55 budesonide pMDI 55 elevated LDL cholesterol 55 sulphonylureas 55 prostate cancer CaP 55 vasoactive 55 Torisel 55 zonisamide SR 55 DAS# remission 55 thromboembolic 55 vidofludimus 55 serum phosphate 55 albuminuria 55 SCIg 55 baseline HbA1c 55 Onrigin 55 denileukin diftitox 55 ACZ# 55 Etanercept 55 uricase 55 pegylated interferon alfa 2b 55 visilizumab 55 ACR# ACR# 55 glycated hemoglobin levels 55 hypereosinophilic syndrome 55 peritumoral brain edema 55 nonvertebral fractures 55 quinolone 55 monoclonal anti 55 Kepivance 55 pharmacodynamic PD 55 immunomodulatory therapies 55 remission induction 55 postexposure prophylaxis 55 MYLOTARG 55 ACTEMRA TM 55 hMG 55 follicular lymphoma FL 55 migraine prophylaxis 55 definite stent thrombosis 55 doxorubicin docetaxel 55 Atacand ® 55 serum phosphate levels 55 dosing frequency 55 NFV 55 anticholinergic agents 55 Clinical Practice Guideline 55 UACR 55 serum uric acid 55 polycythemia vera essential thrombocythemia 55 papillary renal cell carcinoma 55 preserved ejection fraction 55 glulisine 55 subscale scores 55 glucocorticoid induced osteoporosis 55 FluCAM arm 55 nitroprusside 55 non valvular atrial 55 hypercholesterolaemia 55 calcineurin inhibitors 55 levodopa carbidopa 55 intracerebral hemorrhage 55 balsalazide 55 Systemic Lupus Erythematosus SLE 55 serum vitamin D 55 Cimzia TM 55 hypertensives 55 Hypertriglyceridemia 55 ISTODAX 55 Angiox R 55 Inhaled AAT 55 serum retinol 55 corifollitropin alfa 55 pulmonary exacerbations 55 ertapenem 54 juvenile idiopathic arthritis JIA 54 atorvastatin #mg 54 cardiovascular morbidity 54 chronic bronchitis AECB 54 thrombotic events 54 Tolvaptan 54 serum triglycerides 54 phase IIIb 54 tipranavir r 54 Mimpara 54 receptor blocker 54 ORAL HYCAMTIN 54 liver histology 54 selective inhibition 54 intranasal corticosteroid 54 Trandolapril 54 dose Iluvien 54 exhaled nitric oxide 54 SRBD 54 Fingolimod 54 CCyR 54 adenoma recurrence 54 lipid lowering agents 54 Aliskiren 54 arterial hypertension 54 serum leptin 54 Anticoagulation 54 hypercalcemia 54 pharmacologic therapy 54 plus COPEGUS 54 vitamin D inadequacy 54 portal vein thrombosis 54 mg BID dose 54 Prospective Randomized 54 mineralocorticoid 54 milrinone 54 certolizumab pegol 54 systemic JIA 54 SHPT 54 Bosentan 54 CTAP# Capsules 54 Lamotrigine 54 anti arrhythmic drug 54 chromium supplementation 54 symptomatic VTE 54 pyridostigmine 54 AChE inhibitors 54 pregabalin 54 Cardiotoxicity 54 HbA 1c 54 fluticasone propionate FP 54 variceal bleeding 54 HeFH 54 antidiabetic therapy 54 ACR# response 54 angiotensin converting enzyme 54 BARACLUDE r 54 etiologic 54 Double Blind Randomized 54 schizophrenia CIAS 54 Asacol R 54 habitual snoring 54 idarubicin 54 NCCN guidelines 54 primary biliary cirrhosis 54 nonalcoholic steatohepatitis NASH 54 anticholinergics 54 4mg/kg 54 DFMO 54 ergocalciferol 54 steroid dexamethasone 54 donepezil Aricept 54 alefacept 54 PEG IFN 54 Non Alcoholic Steatohepatitis 54 interferon lozenges 54 antithrombotic 54 BEXXAR Therapeutic Regimen 54 serum urate levels 54 desvenlafaxine succinate 54 unstable angina pectoris 54 Allogeneic 54 PCWP 54 subclinical hypothyroidism 54 SSc 54 HIV HCV coinfected 54 lupus nephritis 54 azacytidine 54 allopurinol 54 postprandial glycemia 54 seropositivity 54 stavudine d4T 54 glomerular filtration 54 budesonide formoterol 54 thrombocytopenic 54 anticoagulation therapy 54 macrovascular disease 54 Severe Sepsis 54 acute bronchospasm 54 ranolazine 54 warfarin sodium 54 aminotransferase levels 54 PKC# 54 NOMID 54 biologic DMARDs 54 heavily pretreated 54 SJIA 54 dose atorvastatin 54 Perforomist Inhalation Solution 54 hepatic cirrhosis 54 plasminogen activators 54 NSAID therapy 54 salmeterol HFA MDI 54 fasting plasma 54 lipid lowering therapy 54 prostanoid 54 intracranial stenosis 54 ionophore 54 AAT deficiency 54 antiemetics 54 PEGylated interferon beta 1a 54 Unstable Angina 54 serum cholesterol 54 LEXIVA r 54 nonfasting triglyceride levels 54 serum calcium levels 54 hyperoxaluria 54 immunomodulatory therapy 54 chemoradiotherapy 54 anti androgen 54 fosbretabulin 54 mIU L 54 IFN beta 1a 54 urinary N telopeptide 54 1 Antitrypsin Deficiency 54 LANTUS ® 54 DAPT 54 PsA 54 eculizumab therapy 54 pulmonary hypertension PH 54 ABCB1 54 cefepime 54 TMS Therapy 54 LGG 54 reteplase 54 Controlled Trial 54 glycosylated hemoglobin HbA1c 54 1 proteinase inhibitor 54 hypercholesterolemia 54 rFSH 54 mL/min/#.# m 2 54 imatinib therapy 54 glucose homeostasis 54 sulfasalazine 54 potassium sparing diuretics 54 invasive aspergillosis 54 Platinol ® cisplatin 54 angiotensin receptor blockers ARBs 53 Nebulized 53 hypomethylating agents 53 adiponectin concentrations 53 histologically confirmed 53 LPS induced 53 μmol L 53 inhaled cyclosporine 53 serum lipid levels 53 EXJADE 53 tigecycline 53 Cinacalcet 53 lacosamide 53 Tiotropium 53 resistant hypertension 53 atopic 53 ARCOXIA 53 NYHA functional class 53 Paxil paroxetine 53 CHAMPION PCI 53 Nonalcoholic Fatty Liver Disease 53 CC genotype 53 Sevelamer 53 methylprednisolone 53 Hepatic 53 biologic plausibility 53 GHRH 53 landmark ATHENA trial 53 idiopathic pulmonary arterial hypertension 53 EBRT 53 gene polymorphism 53 vismodegib 53 Erythropoiesis Stimulating Agents 53 torsade de pointes 53 noncardiovascular mortality 53 mixed hyperlipidemia 53 Non inferiority 53 multikinase inhibitor 53 thyrotropin levels 53 atherogenic dyslipidemia 53 gallstone disease 53 heparanase 53 myocardial revascularization 53 systolic hypertension 53 carvedilol 53 Microalbuminuria 53 BPH LUTS 53 onset diabetes mellitus 53 hypovitaminosis D 53 calcitriol 53 antiarrhythmic 53 Tumor Necrosis Factor 53 Acute Ischemic Stroke 53 #.#mg/dL 53 Interferon alfa 53 Zentase 53 ziconotide 53 Prolongs Survival 53 interstitial brachytherapy 53 reflux esophagitis 53 Pharmacologic 53 NIDDM 53 diabetic gastroparesis 53 IGFD 53 epoetin beta 53 isoproterenol 53 Interferon beta 1a 53 PHPT 53 asthma exacerbation 53 inhaled nitric oxide 53 pegylated interferon ribavirin 53 FOLPI 53 Plaque Psoriasis 53 subclinical atherosclerosis 53 paroxysmal AF 53 intestinal permeability 53 AA Amyloidosis 53 CYP #A# 53 serum parathyroid hormone 53 prucalopride 53 neuropsychiatric symptoms 53 receptor antagonism 53 neuroleptic 53 depsipeptide 53 chronic periodontitis 53 percutaneous transluminal coronary angioplasty 53 eosinophilic asthma 53 PON1 activity 53 asymptomatic hyperuricemia 53 Kinoid 53 hepatorenal syndrome 53 Triapine R 53 TZD 53 CANCIDAS 53 glucocorticoid induced 53 lymphoproliferative disorders 53 sargramostim 53 anticholinergic medications 53 LUTS 53 dopaminergic therapy 53 pharmacokinetic interactions 53 ACTH 53 interferon beta therapy 53 IFN alfa 53 Helicobacter pylori infection 53 serum triglyceride 53 Attention-Deficit/Hyperactivity Disorder 53 Glatiramer acetate 53 Septic Shock 53 hypothalamic amenorrhea 53 de novo AML 53 juvenile idiopathic arthritis 53 tolterodine 53 CLL SLL 53 hypogonadal men 53 achieved sustained virological 53 acute GvHD 53 guanfacine extended release 53 Major Depressive Disorder 53 BCG refractory 53 hepatotoxicity 53 coronary stenosis 53 atherosclerotic renal artery stenosis 53 MERLIN TIMI 53 atherothrombotic 53 HLA DR4 53 clinicopathological features 53 Biological Effects 53 Solid Tumors criteria 53 serum urate 53 sustained virological response 53 paclitaxel poliglumex 53 Allergic Rhinitis 53 cirrhotic patients 53 Gheorghiade 53 abdominal adiposity 53 alagebrium 53 Citicoline 53 oral Hycamtin 53 HoFH 53 Hazard Ratio 53 Attention-Deficit/Hyperactivity Disorder ADHD 53 TEMODAL 53 urinary calcium 53 airway hyperresponsiveness 53 OSAHS 53 benign prostatic hypertrophy BPH 53 octreotide 53 sCD# 53 dose dependently 53 Adrenergic 53 external beam radiotherapy 53 depressive symptomatology 53 IL 1ß 53 saline placebo 53 homocysteine concentrations 53 serum cortisol 53 MPS VI 53 progressive dyspnea 53 Polymorphisms 53 rhinoconjunctivitis 53 Systemic Lupus Erythematosus 53 Relapsing Multiple Sclerosis 53 CYT# QbG# 53 golimumab CNTO 53 Dasatinib 53 bronchopulmonary dysplasia 53 mepolizumab 53 asymptomatic carotid stenosis 53 atopic disease 53 chronic idiopathic thrombocytopenic purpura 53 urinary excretion 53 cystoid macular edema 53 conventional DMARDs 53 phosphodiesterase inhibitors 53 patientswith 53 primary hypercholesterolemia 53 tinidazole 53 hydrochloride capsules 53 5 Fluorouracil 53 ALT elevations 53 methacholine challenge 53 left ventricular systolic 53 oral diclofenac 53 pharmacologic intervention 53 IGIV 53 inhalation powder 53 diabetes mellitus DM 53 Bosutinib 53 anagrelide 53 renal scarring 53 PD LID 53 AERIUS 53 SomatoKine 53 rheumatoid factor 53 periprocedural MI 53 Lung Transplantation 53 immune modulating 53 eNO 53 VaD 52 interferon IFN 52 bisphosphonate therapy 52 invasive candidiasis 52 Ranibizumab 52 lanreotide 52 overactive bladder symptoms 52 mITT population 52 oesophageal adenocarcinoma 52 Chemophase 52 pamidronate 52 formoterol fumarate 52 Adverse Event 52 Relapsing Remitting Multiple Sclerosis 52 medroxyprogesterone acetate MPA 52 renal toxicity 52 intermittent dosing 52 neoadjuvant chemotherapy 52 STN stimulation 52 acute humoral rejection 52 adenotonsillectomy 52 sunitinib 52 receptor blockers ARBs 52 cytogenetic abnormalities 52 antihypertensive 52 ASSERT 52 dexrazoxane 52 adrenergic agonists 52 receptor inhibitor 52 carotid artery stenting CAS 52 ejection fractions 52 urine albumin 52 alemtuzumab treated 52 OvaRex MAb 52 intraventricular hemorrhage 52 velafermin 52 overactive bladder OAB 52 hyperlipidaemia 52 clevidipine 52 Vaprisol 52 fluoxetine paroxetine 52 hematopoietic cancers 52 Renal Physicians 52 sevelamer 52 hyperkalemia 52 Pneumococcal vaccination 52 agonist LABA 52 colorectal liver metastases 52 #q# deletion syndrome 52 multimodality therapy 52 Aldosterone 52 viral kinetics 52 contrast induced nephropathy 52 Relapsing remitting 52 teriflunomide 52 intravesical therapy 52 OAB symptoms 52 COZAAR 52 advanced adenoma 52 Vimpat R 52 CG# [003] 52 Ziprasidone 52 transcranial Doppler ultrasound 52 Eltrombopag 52 ICD shocks 52 Tanespimycin 52 ORWH 52 hepatic encephalopathy HE 52 Interferon beta 52 rifamycins 52 mRCC 52 HBeAg negative patients 52 eicosapentaenoic acid 52 Conjugated linoleic acid 52 atrioventricular block 52 Endarterectomy 52 multivariable analysis 52 active ankylosing spondylitis 52 fibromyalgia syndrome 52 serologically active patients 52 AIR2 Trial 52 Kaplan Meier analysis 52 Vascular Disease Foundation 52 reflux symptoms 52 Juvenile Idiopathic Arthritis 52 DAS# scores 52 biliary tract cancer 52 nonadherence 52 sunitinib malate 52 short acting bronchodilator 52 dosing cohort 52 antibody titer 52 NARAC 52 RAPAFLO R 52 Randomized Evaluation 52 macrolide antibiotics 52 warfarin therapy 52 Orphan Designation 52 atherosclerotic disease 52 polyarticular JIA 52 Primary IGFD 52 ganciclovir 52 epoprostenol 52 cerebral vasospasm 52 ACR# responses 52 fasting glucose levels 52 dietary modification 52 serum HBV DNA 52 overt nephropathy 52 undetectable HBV DNA 52 psychiatric comorbidity 52 Onrigin TM 52 hepatic encephalopathy 52 teriparatide 52 neuroregenerative 52 REACH Registry 52 allogeneic hematopoietic stem cell 52 trabectedin 52 QVAR 52 myeloperoxidase 52 AZILECT ® 52 stable angina 52 attention-deficit/hyperactivity disorder ADHD 52 RezularTM 52 kidney allograft 52 Adenomas 52 Silodosin 52 clinicopathological 52 urothelial cancer 52 YONDELIS 52 glycemic variability 52 Reduces Mortality 52 Antitumor 52 HBeAg seroconversion 52 ALLHAT 52 Cannabinoid 52 psychiatric comorbidities 52 isolated systolic hypertension 52 Idiopathic 52 Acute Coronary Syndromes ACS 52 extrapyramidal symptoms 52 NMIBC 52 medullary thyroid carcinoma 52 elevated homocysteine 52 subcutaneous immunoglobulin 52 arterial thromboembolic events 52 Valproic acid 52 CORD II 52 Bipolar Mania 52 inducible nitric oxide synthase 52 clinico pathological 52 recurrent GBM 52 leiomyomas 52 IFN α 52 EoE 52 fructose intolerance 52 Arteriosclerosis 52 hyperhomocysteinemia 52 CoQ 52 ICAEL 52 NAFLD 52 Ocrelizumab 52 haematologic 52 ISTODAX ® 52 endothelin receptor antagonists 52 KDOQI 52 ACNP 52 Androgel R 52 adrenalectomy 52 Remicade infliximab 52 effector function 52 GSTM1 gene 52 bexarotene 52 Amrubicin 52 CALGB 52 pT2 52 bosentan 52 LV dysfunction 52 CRp 52 allogeneic SCT 52 Soft Tissue Sarcoma 52 CYP #D# 52 cyanocobalamin 52 metastatic neuroendocrine tumors 52 plasma pharmacokinetics 52 CRRT 52 #mg/dl 52 DVT PE 52 serine protease inhibitor 52 CIPN 52 idiopathic generalized epilepsy 52 Dacogen decitabine 52 diabetes mellitus 52 diabetic polyneuropathy 52 vinca alkaloid 52 adjuvant endocrine therapy 52 hyperammonemia 52 GG genotype 52 TNF alpha inhibitor 52 Non Responders 52 Alitretinoin 52 myocardial ischemia 52 NMES 52 atopy 52 busulfan 52 detrusor overactivity 52 COPD exacerbation 52 GRNCM1 52 alpha1 proteinase inhibitor 52 aged ≥ 52 intrathecal baclofen 52 cerebrovascular accident 52 Abrupt discontinuation 52 STRIDE PD 52 â ‰ ¥ 52 osteoporotic vertebral fractures 52 IBS C 52 TRO# 52 ACE inhibitors 52 Hb A1C 52 HbA1C 52 ACOMPLIA R 52 paclitaxel eluting stents 52 periprocedural 52 systemic lupus erythematosus 52 Atherosclerotic 52 Mycophenolate mofetil 52 HCV Protease Inhibitor 52 arterial calcification 52 Alvesco R 52 serum ALT 52 tipifarnib 52 adrenergic receptor agonists 52 hyperparathyroidism 52 Yondelis ® 52 Personal CGM 52 Certican 52 Urocortin 2 52 vitro cytotoxicity 52 dyspnoea 52 corticosteroid 52 erection hardness 52 RYGB 52 HGPIN 52 pomalidomide 52 eosinophilic pneumonia 52 APTIVUS R 52 Acute Decompensated Heart Failure 52 neurocognitive impairment 52 epirubicin 52 Rheumatoid Arthritis RA 52 Cardiopulmonary bypass 52 Parnate 52 blood phenylalanine Phe 52 immunopathology 52 antimuscarinic 52 pulmonary exacerbation 52 aromatase inhibitors AIs 51 neurological manifestations 51 Febuxostat 51 Retreatment 51 BCNS 51 tHcy 51 chronic myocardial ischemia 51 neoadjuvant 51 subtrochanteric 51 glycated hemoglobin HbA1c 51 Estradiol 51 systemic hypotension 51 Gynecologic Oncology Group 51 #mg QD [002] 51 Atacand 51 Nocturia 51 ASBMR 51 immunocompetent 51 Clinical Efficacy 51 Lenocta 51 GW# [003] 51 APPRAISE 51 HOMA IR 51 XELOX 51 pharmacokinetic characteristics 51 Investigational Drug 51 systolic dysfunction 51 latanoprost 51 Gamunex C 51 r hGH 51 Nephrogenic 51 vWF 51 Myelodysplastic Syndromes MDS 51 sitaxsentan 51 serum folate concentrations 51 dietary folate 51 inhibitor RG# 51 Orally Active 51 idebenone 51 Investigator Initiated 51 dietary supplementation 51 Hsp# Inhibitor 51 Xelox 51 Carotid endarterectomy 51 Newly Diagnosed Multiple Myeloma 51 phosphate binders 51 plasma homocysteine 51 QD dosing 51 venous thromboembolic disease 51 Vidaza azacitidine 51 Pulmonary Arterial Hypertension 51 Hospital Acquired Pneumonia 51 Interstitial Cystitis 51 Phase Ib Clinical Trial 51 IUGR 51 metastatic gastric 51 lipid abnormalities 51 associated vasculitis 51 Cardiorespiratory fitness 51 coagulation abnormalities 51 basal cell nevus syndrome 51 induce orthostatic hypotension 51 hypomethylating agent 51 Cinacalcet HCl 51 CrCl 51 sunitinib Sutent 51 sodium glucose cotransporter